Novo Nordisk's Hemophilia Drug Was Ready. The Factory Wasn't.

So what went wrong?

When the Factory Fails the Drug

Before the FDA approves any biologic, inspectors visit the manufacturing facility to make sure it meets current Good Manufacturing Practice (cGMP) standards. These inspections are thorough, covering everything from contamination controls to equipment maintenance to staff training. If the site isn't up to par, approval doesn't happen. Period.

For denecimig, the FDA conducted a pre-license inspection of Novo's manufacturing site and came back with a list of things that needed fixing. The company has been working on remediation, but it's not done yet. And the FDA isn't going to approve a drug rolling off a production line that doesn't meet its standards, no matter how good the clinical data looks.

This isn't unprecedented. Novo Nordisk has been dealing with broader manufacturing headaches in 2025 and 2026. The company received a warning letter in March 2026 related to its Plainsboro, New Jersey facility over failures to report serious adverse drug experiences within the required 15-day window. Separately, its Bloomington, Indiana plant (acquired from Catalent) has faced its own cGMP issues, with reports of contamination, pest, and equipment-related findings.

Novo says the denecimig delay doesn't affect its other marketed products and won't change its 2026 financial outlook. But the optics aren't great when multiple facilities are drawing FDA scrutiny at once.

This Happens More Than You'd Think

Manufacturing problems derailing drug approvals is a recurring theme in biotech, and it's one of the industry's most frustrating failure modes. You can spend a billion dollars and a decade proving your drug works, only to stumble because the building where you make it has a quality control gap.

Scholar Rock hit a similar wall with its spinal muscular atrophy drug apitegromab in 2024. According to FDA data, CMC (chemistry, manufacturing, and controls) issues are among the most frequent causes of Complete Response Letters for biologics applications.

It's like getting your restaurant reviewed by a Michelin inspector: you could have the best chef in the world, but if the kitchen fails the health inspection, you're not opening.

A Crowded Race With No Room for Delays

The timing is particularly painful for Novo because the hemophilia A market is getting crowded fast. Roche's Hemlibra (emicizumab) already owns the non-factor prophylaxis category and has set the commercial benchmark. Novo Nordisk's Alhemo (concizumab), a different type of therapy called a rebalancing agent, recently won U.S. approval for patients aged 12 and older without inhibitors. And the broader pipeline is massive; analysts count 40 to 80+ companies developing hemophilia A therapies, depending on how broadly you define the competitive set.

Denecimig was supposed to be Novo's answer to Hemlibra, potentially offering comparable efficacy with a smaller injection volume and more flexible dosing. Every month of delay is a month where competitors consolidate their positions and physician prescribing habits get harder to change.

What Comes Next

Novo Nordisk says it still aims for a U.S. launch in the first half of 2027, which suggests the company believes remediation can be wrapped up in time for a late 2026 or early 2027 FDA decision. But without a revised action date from the agency, that's more hope than certainty.

The key variable now is execution speed at the manufacturing site. If Novo can resolve the facility issues quickly, this becomes a footnote: a few-month blip on what should be a successful launch. If remediation drags on, or if the FDA comes back with additional findings, the delay could stretch well into 2027.

For investors, the signal is mixed. The drug itself remains intact, and the company's 2026 guidance is unchanged. But manufacturing problems have a way of compounding. When the FDA starts pulling threads at your facilities, the fixes rarely come as fast as you'd like.

Denecimig cleared the hard part: proving it works in patients. Now it just needs a factory that can pass a test. That shouldn't be the hardest part of bringing a drug to market, and yet, here we are.

The $4 Billion ADC Bet That Just Hit a Wall

Daiichi Sankyo and Merck pulled their FDA application for a lung cancer ADC just two weeks before the decision date. The reason signals a seismic shift in how the FDA evaluates accelerated approvals, and dozens of ADC programs should be worried.